ANI PHARMACEUTICALS INC - ANIP
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 500.0 | 77.95 | 38,975.0 | 78,890.0 | View | |
| Mar 13, 2026 | HEAD OF RARE DISEASE | S | D | 3,162.0 | 71.64 | 226,525.68 | 91,309.0 | View | |
| Mar 13, 2026 | SVP, HEAD - ESTABLISHED BRANDS | S | D | 4,772.0 | 74.91 | 357,470.52 | 38,730.0 | View | |
| Mar 13, 2026 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 500.0 | 72.62 | 36,310.0 | 79,390.0 | View | |
| Mar 10, 2026 | SVP & CFO | F | D | 5,150.0 | 74.04 | 381,306.0 | 180,393.0 | View | |
| Mar 10, 2026 | SVP, CHIEF HR OFFICER | S | D | 5,087.0 | 74.13 | 377,099.31 | 51,946.0 | View | |
| Mar 10, 2026 | SVP, CHIEF HR OFFICER | S | D | 1,485.0 | 75.0 | 111,375.0 | 57,033.0 | View | |
| Mar 10, 2026 | SVP, GENERICS | F | D | 3,314.0 | 74.04 | 245,368.56 | 81,468.0 | View | |
| Mar 10, 2026 | PRESIDENT & CEO | F | D | 17,060.0 | 74.04 | 1,263,122.4 | 404,889.0 | View | |
| Mar 10, 2026 | HEAD OF RARE DISEASE | S | D | 3,602.0 | 74.18 | 267,196.36 | 94,471.0 | View | |
| Mar 10, 2026 | HEAD OF RARE DISEASE | F | D | 3,314.0 | 74.04 | 245,368.56 | 98,073.0 | View | |
| Mar 10, 2026 | HEAD OF RARE DISEASE | S | D | 2,121.0 | 74.22 | 157,420.62 | 101,387.0 | View | |
| Mar 05, 2026 | SVP & CFO | M | D | 3,312.0 | 49.51 | 163,977.12 | 9,938.0 | View | |
| Mar 05, 2026 | SVP & CFO | S | D | 4,000.0 | 75.56 | 302,240.0 | 185,543.0 | View | |
| Mar 05, 2026 | SVP & CFO | S | D | 3,312.0 | 75.42 | 249,791.04 | 189,543.0 | View | |
| Mar 05, 2026 | SVP & CFO | M | A | 3,312.0 | 49.51 | 163,977.12 | 192,855.0 | View | |
| Mar 04, 2026 | HEAD OF RARE DISEASE | S | D | 417.0 | 74.0 | 30,858.0 | 103,508.0 | View | |
| Mar 04, 2026 | SVP, GENERICS | S | D | 2,060.0 | 76.5 | 157,590.0 | 84,782.0 | View | |
| Mar 03, 2026 | — | S | D | 6,000.0 | 74.23 | 445,380.0 | 52,405.0 | View | |
| Mar 02, 2026 | SVP & CFO | F | D | 2,773.0 | 73.9 | 204,924.7 | 189,543.0 | View | |
| Mar 02, 2026 | SVP & CFO | A | A | 22,233.0 | 77.15 | 1,715,275.95 | 192,316.0 | View | |
| Mar 02, 2026 | SR. VP, GENERAL COUNSEL & SEC. | F | D | 1,555.0 | 73.9 | 114,914.5 | 79,890.0 | View | |
| Mar 02, 2026 | SR. VP, GENERAL COUNSEL & SEC. | A | A | 13,895.0 | 77.15 | 1,071,999.25 | 81,445.0 | View | |
| Mar 02, 2026 | SVP, CHIEF HR OFFICER | F | D | 1,555.0 | 73.9 | 114,914.5 | 58,518.0 | View | |
| Mar 02, 2026 | SVP, CHIEF HR OFFICER | A | A | 10,810.0 | 77.15 | 833,991.5 | 60,073.0 | View | |
| Mar 02, 2026 | SVP - CORP. DEV. & STRATEGY | F | D | 2,221.0 | 73.9 | 164,131.9 | 74,916.0 | View | |
| Mar 02, 2026 | SVP - CORP. DEV. & STRATEGY | A | A | 11,116.0 | 77.15 | 857,599.4 | 77,137.0 | View | |
| Mar 02, 2026 | SVP, GENERICS | F | D | 2,221.0 | 73.9 | 164,131.9 | 86,842.0 | View | |
| Mar 02, 2026 | SVP, GENERICS | A | A | 12,969.0 | 77.15 | 1,000,558.35 | 89,063.0 | View | |
| Mar 02, 2026 | PRESIDENT & CEO | F | D | 12,217.0 | 73.9 | 902,836.3 | 421,949.0 | View | |
| Mar 02, 2026 | PRESIDENT & CEO | A | A | 75,592.0 | 77.15 | 5,831,922.8 | 434,166.0 | View | |
| Mar 02, 2026 | HEAD OF RARE DISEASE | F | D | 2,221.0 | 73.9 | 164,131.9 | 103,925.0 | View | |
| Mar 02, 2026 | HEAD OF RARE DISEASE | A | A | 21,306.0 | 77.15 | 1,643,757.9 | 106,146.0 | View | |
| Mar 02, 2026 | SVP, HEAD - ESTABLISHED BRANDS | F | D | 628.0 | 73.9 | 46,409.2 | 43,502.0 | View | |
| Mar 02, 2026 | SVP, HEAD - ESTABLISHED BRANDS | A | A | 6,021.0 | 77.15 | 464,520.15 | 44,130.0 | View | |
| Mar 02, 2026 | HEAD OF R&D, COO-NOVITIUM OPS | A | A | 11,116.0 | 77.15 | 857,599.4 | 101,056.0 | View | |
| Feb 23, 2026 | HEAD OF RARE DISEASE | S | D | 5,323.0 | 78.02 | 415,300.46 | 84,840.0 | View | |
| Feb 23, 2026 | SVP, CHIEF HR OFFICER | S | D | 1,730.0 | 77.99 | 134,922.7 | 49,263.0 | View | |
| Feb 23, 2026 | SVP, CHIEF HR OFFICER | S | D | 2,084.0 | 77.53 | 161,572.52 | 50,993.0 | View | |
| Feb 17, 2026 | SVP & CFO | F | D | 2,448.0 | 77.36 | 189,377.28 | 170,083.0 | View | |
| Feb 17, 2026 | SVP & CFO | F | D | 2,829.0 | 76.7 | 216,984.3 | 172,531.0 | View | |
| Feb 17, 2026 | SVP, CHIEF HR OFFICER | F | D | 1,290.0 | 77.36 | 99,794.4 | 53,077.0 | View | |
| Feb 17, 2026 | SVP, CHIEF HR OFFICER | F | D | 1,180.0 | 76.7 | 90,506.0 | 54,367.0 | View | |
| Feb 17, 2026 | SVP - CORP. DEV. & STRATEGY | F | D | 1,717.0 | 77.36 | 132,827.12 | 66,021.0 | View | |
| Feb 17, 2026 | SVP - CORP. DEV. & STRATEGY | F | D | 1,608.0 | 76.7 | 123,333.6 | 67,738.0 | View | |
| Feb 17, 2026 | SVP, GENERICS | F | D | 1,888.0 | 77.36 | 146,055.68 | 76,094.0 | View | |
| Feb 17, 2026 | SVP, GENERICS | F | D | 1,775.0 | 76.7 | 136,142.5 | 77,982.0 | View | |
| Feb 17, 2026 | PRESIDENT & CEO | F | D | 10,298.0 | 77.36 | 796,653.28 | 358,574.0 | View | |
| Feb 17, 2026 | PRESIDENT & CEO | F | D | 11,688.0 | 76.7 | 896,469.6 | 368,872.0 | View | |
| Feb 17, 2026 | HEAD OF RARE DISEASE | F | D | 2,403.0 | 77.36 | 185,896.08 | 90,163.0 | View | |
| Feb 17, 2026 | HEAD OF RARE DISEASE | S | D | 7,032.0 | 76.55 | 538,299.6 | 92,566.0 | View | |
| Feb 17, 2026 | HEAD OF RARE DISEASE | F | D | 3,173.0 | 76.7 | 243,369.1 | 99,598.0 | View | |
| Feb 17, 2026 | SVP, HEAD - ESTABLISHED BRANDS | F | D | 485.0 | 77.36 | 37,519.6 | 38,109.0 | View | |
| Feb 17, 2026 | SVP, HEAD - ESTABLISHED BRANDS | F | D | 566.0 | 76.7 | 43,412.2 | 38,594.0 | View | |
| Feb 17, 2026 | SR. VP, GENERAL COUNSEL & SEC. | F | D | 1,779.0 | 77.36 | 137,623.44 | 67,550.0 | View | |
| Feb 17, 2026 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 500.0 | 76.8 | 38,400.0 | 69,329.0 | View | |
| Feb 17, 2026 | SR. VP, GENERAL COUNSEL & SEC. | F | D | 1,534.0 | 76.7 | 117,657.8 | 69,829.0 | View | |
| Feb 13, 2026 | HEAD OF R&D, COO-NOVITIUM OPS | F | D | 2,898.0 | 76.25 | 220,972.5 | 89,940.0 | View | |
| Feb 13, 2026 | SVP, HEAD - ESTABLISHED BRANDS | F | D | 1,762.0 | 76.25 | 134,352.5 | 39,160.0 | View | |
| Feb 13, 2026 | HEAD OF RARE DISEASE | F | D | 4,546.0 | 76.25 | 346,632.5 | 102,771.0 | View | |
| Feb 13, 2026 | PRESIDENT & CEO | F | D | 30,659.0 | 76.25 | 2,337,748.75 | 380,560.0 | View | |
| Feb 13, 2026 | SVP, GENERICS | F | D | 4,267.0 | 76.25 | 325,358.75 | 79,757.0 | View | |
| Feb 13, 2026 | SVP - CORP. DEV. & STRATEGY | F | D | 4,269.0 | 76.25 | 325,511.25 | 69,346.0 | View | |
| Feb 13, 2026 | SVP, CHIEF HR OFFICER | F | D | 3,017.0 | 76.25 | 230,046.25 | 55,547.0 | View | |
| Feb 13, 2026 | SR. VP, GENERAL COUNSEL & SEC. | F | D | 3,011.0 | 76.25 | 229,588.75 | 71,363.0 | View | |
| Feb 13, 2026 | SVP & CFO | F | D | 5,503.0 | 76.25 | 419,603.75 | 175,360.0 | View | |
| Jan 14, 2026 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 500.0 | 84.33 | 42,165.0 | 74,374.0 | View | |
| Dec 19, 2025 | SVP, CHIEF HR OFFICER | S | D | 1,622.0 | 82.4 | 133,652.8 | 58,564.0 | View | |
| Dec 12, 2025 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 400.0 | 82.32 | 32,928.0 | 74,874.0 | View | |
| Dec 09, 2025 | — | S | D | 1,800.0 | 81.15 | 146,070.0 | 25,157.0 | View | |
| Nov 17, 2025 | — | G | D | 3,000.0 | 0.0 | 0.0 | 58,405.0 | View | |
| Nov 17, 2025 | — | S | D | 8,643.0 | 86.88 | 750,903.84 | 61,405.0 | View | |
| Nov 14, 2025 | SR. VP, GENERAL COUNSEL & SEC. | S | D | 400.0 | 87.27 | 34,908.0 | 75,274.0 | View | |
| Nov 14, 2025 | SVP - CORP. DEV. & STRATEGY | S | D | 94.0 | 88.0 | 8,272.0 | 158,490.0 | View | |
| Nov 14, 2025 | SVP - CORP. DEV. & STRATEGY | S | D | 14,642.0 | 89.07 | 1,304,162.94 | 158,584.0 | View |